At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Progesterone for the Treatment of Cannabis Withdrawal
In Brief
A Early Phase 1 clinical trial evaluating Progesterone and Placebo for Cannabis Use Disorder and Cannabis Withdrawal. Completed, enrolled 8 participants across 1 site.
Detailed Summary
Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options. Ovarian hormones have been identified as potential mechanisms of these disparities , and recent clinical trials have begun to examine their utility as possible pharmacotherapeutic agents. The ovarian hormone progesterone has shown promise as a treatment for female cocaine and nicotine users, but has not yet been tested for cannabis. Gender differences in cannabis withdrawal, which is associated with relapse, are pronounced and several studies report more severe and impairing withdrawal symptoms in women compared to men. Developing pharmacological interventions for cannabis withdrawal remains an important priority given the significant cognitive, psychiatric, and physical consequences of heavy cannabis use.
Study Details
Timeline
Interventions
Progesterone capsule
Placebo capsule. Manufactured to mimic progesterone 200mg capsule.